PUBLISHER: Grand View Research | PRODUCT CODE: 1362980
PUBLISHER: Grand View Research | PRODUCT CODE: 1362980
The Europe hyaluronic acid-based dermal fillers market size is expected to reach USD 2.13 billion by 2030, registering a CAGR of 9.1% from 2023 to 2030, according to a new report by Grand View Research, Inc.. Rapidly aging population, large number of cosmetic surgeries performed, and technological advancements are among key factors driving the market. Growing demand to enhance one's aesthetic appeal is resulting in high number of cosmetic surgeries being performed. This can also be attributed to the availability of noninvasive surgical alternatives and rising awareness among consumers. According to the International Society of Aesthetic Plastic Surgery (ISAPS), in 2017, hyaluronic acid-based dermal filler procedures were among the three most preferred noninvasive aesthetic surgeries.
Minimal adverse effects, lesser pain, shorter recovery time, and fewer postsurgical complications are some of the factors driving preference for minimally invasive surgeries. The European market is dominated by well-known brands such as Juvederm, Restylane, and Belotero. In addition, France has several native brands with different patented technologies, thereby contributing to regional market growth. Stylage, Cytosial, Hyaluronica, and Surface Volume are some of the local brands available in the market.
Increasing demand for aesthetic procedures majorly in Italy and Spain is creating a great opportunity for market expansion. According to the ISAPS, about 952,830 aesthetic surgeries were performed in 2016, of which 650,995 were noninvasive procedures such as Botox and dermal fillers.
Various strategic initiatives such as product launch, approvals, and mergers and acquisitions propel the market. For instance, in January 2017, Allergan plc launched Juvederm VOLITE, a new hyaluronic acid dermal filler with its unique patented VYCROSS technology, which lasts for up to nine months. In another instance, in September 2018, Allergan acquired Bonti, Inc. to expand its product portfolio with Bonti's pipeline products such as (BoNT/E) botulinum neurotoxin serotype E in phase II, EB-001T (therapeutic), and EB-001A (aesthetic).